News

TearSolutions, Inc. Appoints Dr. Louis M Alpern to its Board of Directors

TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Louis M Alpern, MD, MPH, FACS, FICS has been appointed to the Company’s Board of Directors.

“Dr. Alpern brings extensive real-world clinical experience treating patients with ocular surface disease, having prescribed or trialed virtually every dry eye treatment available,” said Anil Asrani, President and CEO of TearSolutions. “Dr. Alpern has served as a Principal Investigator in over 100 ophthalmology clinical trials and we welcome his valued perspectives as we continue to advance our clinical programs.”

“I’ve seen, first-hand, the devastating impact that ocular surface disease can have on patients and their families and, as their treating physician, I shared in their frustration with currently available treatment options and the well-known problems associated with them,” said Dr. Alpern. “Given TearSolutions’ approach, the scientific rigor behind the discovery and development of their lacritin-derived peptide therapeutics and the pre-clinical and clinical data that they have generated, I believe that Lacripep has the potential to be a first-line treatment that will be broadly lauded by patients and their care-providers.”

Dr. Alpern has more than four decades of private practice and clinical trialing experience in ophthalmology. He received his Doctor of Medicine from Harvard Medical School and his Master of Public Health from the Harvard School of Public Health.

Read more here.

Recent News

02/05/2025

Project Vital bringing millions in funding to Roanoke-Blacksburg’s life sciences

The Roanoke-Blacksburg region is establishing itself as a biomedical research hub and medical device innovation center. About $5 million from the state could help move that work from labs to markets. Those millions will fund Project Vital: Virginia Innovations and Technology Advancements in Life Sciences. It’s a collaboration among the Roanoke-Blacksburg Innovation Alliance (formerly Verge),

01/31/2025

AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona

AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated

01/30/2025

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who